Testing for human immunodeficiency virus in chemical dependence treatment programs

This article examines the issue of testing for human immunodeficiency virus (HIV) in chemical dependence treatment programs. Three types of treatment programs are considered: 21- to 28-day inpatient, eight-week outpatient, and methadone maintenance. Through discussion by groups of chemical dependence treatment providers, recommendations are made in regard to issues of who to test, when to test, confidential versus anonymous testing, charting policies, informed consent, elements of pre- and posttest counseling, and the duty to warn others.